316 related articles for article (PubMed ID: 25066012)
1. Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a noninferiority randomized controlled trial.
Roozeboom MH; Nelemans PJ; Mosterd K; Steijlen PM; Arits AH; Kelleners-Smeets NW
Br J Dermatol; 2015 Mar; 172(3):739-45. PubMed ID: 25066012
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma.
Arits AH; Spoorenberg E; Mosterd K; Nelemans P; Kelleners-Smeets NW; Essers BA
Br J Dermatol; 2014 Dec; 171(6):1501-7. PubMed ID: 24749843
[TBL] [Abstract][Full Text] [Related]
4. Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU).
Roozeboom MH; van Kleef L; Arits AH; Mosterd K; Winnepenninckx VJ; van Marion AM; Nelemans PJ; Kelleners-Smeets NW
J Am Acad Dermatol; 2015 Jul; 73(1):93-8. PubMed ID: 25935596
[TBL] [Abstract][Full Text] [Related]
5. Three-Year Follow-Up Results of Photodynamic Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial.
Roozeboom MH; Arits AHMM; Mosterd K; Sommer A; Essers BAB; de Rooij MJM; Quaedvlieg PJF; Steijlen PM; Nelemans PJ; Kelleners-Smeets NWJ
J Invest Dermatol; 2016 Aug; 136(8):1568-1574. PubMed ID: 27113429
[TBL] [Abstract][Full Text] [Related]
6. Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolaevulinic acid 20% vs. two-stage topical methyl aminolaevulinate: results of a randomized controlled trial.
Kessels JPHM; Kreukels H; Nelemans PJ; Roozeboom MH; van Pelt H; Mosterd K; de Haas ERM; Kelleners-Smeets NWJ
Br J Dermatol; 2018 May; 178(5):1056-1063. PubMed ID: 28886209
[TBL] [Abstract][Full Text] [Related]
7. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up.
Szeimies RM; Ibbotson S; Murrell DF; Rubel D; Frambach Y; de Berker D; Dummer R; Kerrouche N; Villemagne H;
J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1302-11. PubMed ID: 18624836
[TBL] [Abstract][Full Text] [Related]
8. Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma.
Jansen MHE; Mosterd K; Arits AHMM; Roozeboom MH; Sommer A; Essers BAB; van Pelt HPA; Quaedvlieg PJF; Steijlen PM; Nelemans PJ; Kelleners-Smeets NWJ
J Invest Dermatol; 2018 Mar; 138(3):527-533. PubMed ID: 29045820
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal.
Lecluse LL; Spuls PI
Br J Dermatol; 2015 Jan; 172(1):8-10. PubMed ID: 25581584
[TBL] [Abstract][Full Text] [Related]
10. Conventional and combination topical photodynamic therapy for basal cell carcinoma: systematic review and meta-analysis.
Collier NJ; Haylett AK; Wong TH; Morton CA; Ibbotson SH; McKenna KE; Mallipeddi R; Moseley H; Seukeran D; Ward KA; Mohd Mustapa MF; Exton LS; Green AC; Rhodes LE
Br J Dermatol; 2018 Dec; 179(6):1277-1296. PubMed ID: 29889302
[TBL] [Abstract][Full Text] [Related]
11. A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities.
Aguilar M; de Troya M; Martin L; Benítez N; González M
J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1431-6. PubMed ID: 20456549
[TBL] [Abstract][Full Text] [Related]
12. Sequential Treatment of Superficial Basal Cell Carcinomas With Topical Methyl Aminolevulinate Photodynamic Therapy and Imiquimod 5% Cream: A Retrospective Study of Clinical and Cosmetic Outcomes.
Logan IT; Kulakov EL; Perrett CM
Dermatol Surg; 2020 Oct; 46(10):1272-1278. PubMed ID: 32011386
[TBL] [Abstract][Full Text] [Related]
13. A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy.
Morton CA; Dominicus R; Radny P; Dirschka T; Hauschild A; Reinhold U; Aschoff R; Ulrich M; Keohane S; Ekanayake-Bohlig S; Ibbotson S; Ostendorf R; Berking C; Gröne D; Schulze HJ; Ockenfels HM; Jasnoch V; Kurzen H; Sebastian M; Stege H; Staubach P; Gupta G; Hübinger F; Ziabreva I; Schmitz B; Gertzmann A; Lübbert H; Szeimies RM
Br J Dermatol; 2018 Aug; 179(2):309-319. PubMed ID: 29432644
[TBL] [Abstract][Full Text] [Related]
14. Aminolevulinic acid and methyl aminolevulinate equally effective in topical photodynamic therapy for non-melanoma skin cancers.
Tarstedt M; Gillstedt M; Wennberg Larkö AM; Paoli J
J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):420-3. PubMed ID: 26841041
[TBL] [Abstract][Full Text] [Related]
15. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials.
Roozeboom MH; Arits AH; Nelemans PJ; Kelleners-Smeets NW
Br J Dermatol; 2012 Oct; 167(4):733-56. PubMed ID: 22612571
[TBL] [Abstract][Full Text] [Related]
16. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment.
Horn M; Wolf P; Wulf HC; Warloe T; Fritsch C; Rhodes LE; Kaufmann R; De Rie M; Legat FJ; Stender IM; Solér AM; Wennberg AM; Wong GA; Larkö O
Br J Dermatol; 2003 Dec; 149(6):1242-9. PubMed ID: 14674903
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes.
Caekelbergh K; Nikkels AF; Leroy B; Verhaeghe E; Lamotte M; Vincent R
J Drugs Dermatol; 2009 Nov; 8(11):992-6. PubMed ID: 19894366
[TBL] [Abstract][Full Text] [Related]
18. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up.
Roozeboom MH; Aardoom MA; Nelemans PJ; Thissen MR; Kelleners-Smeets NW; Kuijpers DI; Mosterd K
J Am Acad Dermatol; 2013 Aug; 69(2):280-7. PubMed ID: 23566914
[TBL] [Abstract][Full Text] [Related]
19. Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma.
Annemans L; Caekelbergh K; Roelandts R; Boonen H; Leys C; Nikkels AF; van Den Haute V; van Quickenborne L; Verhaeghe E; Leroy B
Eur J Dermatol; 2008; 18(5):539-46. PubMed ID: 18693157
[TBL] [Abstract][Full Text] [Related]
20. Interventions for cutaneous Bowen's disease.
Bath-Hextall FJ; Matin RN; Wilkinson D; Leonardi-Bee J
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD007281. PubMed ID: 23794286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
